Amarantus Bioscence - WKN: A1J9ZB - MEGA NEWS $$$$


Seite 31 von 67
Neuester Beitrag: 25.04.21 03:33
Eröffnet am:27.12.12 09:39von: AntontAnzahl Beiträge:2.672
Neuester Beitrag:25.04.21 03:33von: InesbcagaLeser gesamt:187.912
Forum:Hot-Stocks Leser heute:153
Bewertet mit:
3


 
Seite: < 1 | ... | 28 | 29 | 30 |
| 32 | 33 | 34 | ... 67  >  

2166 Postings, 5040 Tage MilchKaffeebeachtliches...

 
  
    #751
09.01.13 12:55
... volumen.  

31878 Postings, 5350 Tage tbhomyRubinfeld wird für Amarantus...

 
  
    #752
09.01.13 13:07
...seine Fühler ausstrecken. Seine Verbindungen könnten Gold für Amarantus bedeuten.  

4020 Postings, 5044 Tage ManuBabyLöschung

 
  
    #753
09.01.13 13:08

Moderation
Zeitpunkt: 09.01.13 13:14
Aktion: Löschung des Beitrages
Kommentar: Off-Topic - Bezug zur Aktie nicht ersichtlich

 

 

4020 Postings, 5044 Tage ManuBabyHallo st.:

 
  
    #754
09.01.13 13:20
die Vermillion-Story schein wohl an dir vorbeigegangen zu sein.

Bitte erst informieren in welcher Branche Vermillion tätig ist und dann informieren in welcher Branche Amarantus tätig ist.
Dieser Link ist wahrlich nicht O-Topic.
Der Kursverlau wird es dir zeigen.  

14689 Postings, 5176 Tage falke2dummgelaufen..#754

 
  
    #755
09.01.13 13:24
sollte ein schwarzer werden ;-((  

4020 Postings, 5044 Tage ManuBabyHallo Falke: Nehm mal Kontakt mit dem Mod auf.

 
  
    #756
09.01.13 13:28
Der kann dir bei der Korrektur sicherlich helfen.  Musst viel Zeit haben, wenn du immer noch der Vergangenheit "nachtrauerst".

0.13 / 0.134(1 x 1) .   AMBS gibt heute sicherlich billiger  

14689 Postings, 5176 Tage falke2+++ RT 0,122 +27,08 +++

 
  
    #757
09.01.13 13:34

8229 Postings, 4421 Tage Paradiso1manu ist ein mädchenname

 
  
    #758
2
09.01.13 13:34

7297 Postings, 6239 Tage madeinhellnoch billiger

 
  
    #759
09.01.13 13:45

sehr gut dann kauf ich. was denkst du manu bekomm ich nochmal in meinem leben welche für 0,02?

 

382 Postings, 4741 Tage SemiraJetzt werden die shorter aktiv :)

 
  
    #760
09.01.13 13:52

4020 Postings, 5044 Tage ManuBabyTja madeinhell, das mußt du die Amis fragen

 
  
    #761
09.01.13 13:53
Entweder bekommst noch welche für 0,02 oder kanst für 0,30, 0,40, 0,50, 1,00 verkaufen. Hop oder Top.

Für 0,11 gibt heute sicherlich noch welche.  

4020 Postings, 5044 Tage ManuBabyStimmt nicht Semira Miss, die Shorter sind schon

 
  
    #762
09.01.13 13:56
Monate lang aktiv


Short Sales
Date Short Interest % Change Avg. Daily Share Volume Days to Cover Split New Issue
Dec 14, 2012 849,880 12.69 16,301,056 1.00 No No
Nov 30, 2012 754,142 -59.54 20,565,431 1.00 No No
Nov 15, 2012 1,864,130 12,975.19 40,158,346 1.00 No No
Oct 31, 2012 14,257 -95.47 8,018,765 1.00 No No
Oct 15, 2012 314,583 308.93 6,706,288 1.00 No No
Sept 28, 2012 76,929 134.78 2,294,607 1.00 No No
Sept 14, 2012 32,766 100.00 2,095,452 1.00 No No
Aug 31, 2012 0 -100.00 1,069,364 0.00 No No
Aug 15, 2012 25,456 918.24 338,097 1.00 No No
Jul 31, 2012 2,500 163.44 503,434 1.00 No No
Results Per Page 102050  

31878 Postings, 5350 Tage tbhomyBrewer und Toi Cook sind nur der Anfang...

 
  
    #763
09.01.13 13:59

7297 Postings, 6239 Tage madeinhellkann sein das es dropt

 
  
    #764
09.01.13 14:00

für gewisse leute nur dann wird es nach oben umso heftiger das wenn du us handelst deine orders nicht ausgeführt werden. das haben die auch drauf.

hab auch schon erlebt das unter meinem bid bedient wurde und ich leer ausgegangen bin.

 

2166 Postings, 5040 Tage MilchKaffeegibst du mir mal den link zu den shortsales manu

 
  
    #765
09.01.13 14:00

382 Postings, 4741 Tage Semirashort sales

 
  
    #766
09.01.13 14:10
Sind in den short sales auch die shorts dt. Daytrader drin ?
Mein Broker lässt das shorten von Aktien nur zu, wenn andere Kunden meines Brokers Positionen in der Aktie besitzen. Werden diese "shorts" auch an Finra gemeldet ?  

3512 Postings, 4726 Tage ForscherGucks du ;-))

 
  
    #767
09.01.13 14:12
Real-Time Best Bid & Ask

0.13 / 0.134  

3512 Postings, 4726 Tage ForscherVon grade eben :-))

 
  
    #768
09.01.13 14:16
Nee von gestern Abend Hahahahaha

Brand aktuelle Meldung nur für Deutsche Trader:

            - OTC Nasdaq öffnet heute früher -

Dann sehen wir den oben geführten Kurs nochmal von oben ;-)  

14689 Postings, 5176 Tage falke2News Release

 
  
    #769
09.01.13 14:32
Amarantus BioScience Announces Positive Efficacy Data for MANF in a Nigral Delivery Neurorestoration Animal Model of Parkinson's Disease

2013-01-09 08:31 ET - News Release

SUNNYVALE, Calif., Jan. 9, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with protein misfolding and apoptosis centered around its patented therapeutic protein Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF), today presented positive preclinical efficacy data for MANF in a neurorestoration 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease.  The data demonstrate that unlike Glial cell-Derived Neurotrophic Factor (GDNF), MANF significantly reduces behavioral deficits, increases dopaminergic (DA) nerve terminal reinnervation of the striatum, and increases dopamine concentrations in the striatum when MANF is administered directly to the substantia nigra (SNc).  GDNF is an agent currently in clinical trials for Parkinson's disease. Dr. John W. Commissiong, Chief Scientific Officer of Amarantus, presented the data at the OneMedForum 2013 conference on January 8, 2013. The webcast is available online at http://www.onemedplace.com/database/list/cid/13336/.

"Today's data support previously reported behavioral data where MANF demonstrated superiority over GDNF," said Dr. John W. Commissiong.  "Going forward, the Company is in a strong position to advance MANF as a potential disease-modifying treatment for Parkinson's based on unique behavioral, morphological and neurochemical data in standard animal models of the disease."

In humans and animals, dopamine is a chemical released by DA neurons to send signals to other neurons, and is known as a neurotransmitter. DA neurons are the cells responsible for releasing dopamine, and degenerate in the SNc of Parkinson's disease patients. This degeneration causes DA nerve terminals from the striatum to retract towards their cells bodies in the SNc. The loss of DA nerve terminals in the striatum leads to reduced dopamine levels in the striatum. Therefore, drug treatment to the SNc that increases innervation of the striatum is critical as a basis for functional recovery in Parkinson's disease.

The data produced comparing optimal doses to the SNc of MANF = 10 ug and GDNF = 10 ug in this model indicate the following at four weeks post-treatment:

  1. MANF reduced behavioral deficits by 53%, whereas behavioral deficits with GDNF increased by 20%;
  2. MANF produced a 14.4% reinnervation of the striatum, whereas striatum innervation with GDNF was reduced by 9.9%;
  3. MANF increased dopamine concentrations in the striatum, whereas striatum dopamine concentrations with GDNF did not increase.

"We are excited about our results with MANF as we have demonstrated superiority to GDNF in a number of key areas related to recovery of function in Parkinson's disease," added Dr. Joseph Rubinfeld, Amarantus advisor and Amgen Co-Founder.  "We intend to continue to move our Parkinson's program forward, while also evaluating other disease indications for MANF with potentially accelerated regulatory pathways, including certain orphan diseases. This strategy may significantly reduce MANF's overall time to market versus a Parkinson's-only strategy."

In the study, rodents were lesioned with 6-OHDA on one side of their brain (t = 0).  Behavior was tested for baseline (t =1 week) and vehicle, MANF (3 ug, 10 ug or 36 ug) and GDNF (10ug) were injected in different groups of animals at t = 2 weeks.  Behavior was tested for drug effect at t = 4 weeks (2 weeks post-treatment) and at t = 6 weeks (4 weeks post-treatment).

The behavioral data achieved statistical significance with a p value of less than 0.03 with animal groups of N=12. The striatum reinnervation data and dopamine concentration data did not achieve statistical significance because the animals sacrificed from the behavioral study were divided into 2 separate groups of N=6 for the analysis of densitometry (striatum reinnervation) and neurochemistry (dopamine concentration in the striatum). The method of analysis of the rat brains did not allow for the densitometry and neurochemistry to be analyzed simultaneously in the same animals, leading to groups of N = 6 or less, which was insufficient to achieve statistical significant.

The Company believes the data are positive, even without statistical significance due to small groups of animals in the densitometry and chemistry data, because there are consistent internal results correlating behavior, stereology, densitometry and neurochemistry, most notably at MANF = 10 ug and GDNF = 10ug. The Company is preparing to initiate IND enabling studies for MANF as a disease-modifying drug candidate for Parkinson's disease.

About Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF)

MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a protein that corrects protein misfolding, one of the major causes of apoptosis (Programmed Cell Death). Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) is believed to have broad potential because it is a naturally-occurring protein produced by the body for the purpose of reducing and preventing apoptosis (in response to injury or disease), via the unfolded protein response. By manufacturing MANF and administering it to the body, Amarantus is seeking to use a regenerative medicine approach to assist the body with higher quantities of MANF when needed.  Amarantus is the front-runner and primary holder of intellectual property (IP) around MANF, and is initially focusing on the development of MANF-based protein therapeutics.  MANF's current lead indication is Parkinson's disease with additional focus on Traumatic Brain Injury (TBI).  Future indications may include myocardial infarction and certain rare and ultra-rare orphan diseases where MANF is currently being evaluated.  

The Company also owns an inventory of 88 cell lines referred to as "PhenoGuard Cell Lines." MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line, and it is anticipated that additional therapeutic proteins useful for various therapeutic approaches to the Central Nervous System will be identified from the Company's inventory of PhenoGuard Cell Lines.

About Amarantus BioScience, Inc.

Amarantus BioScience, Inc. is a development-stage biotechnology company founded in January 2008.  The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases.  The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit www.Amarantus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

MEDIA CONTACTS

Amarantus BioScience, Inc.
(408) 737-2734
pr@amarantus.com

Investor/Media Contact:
IR Sense, LLC
Remy Bernarda
415-203-6386
remy@irsense.com

SOURCE Amarantus BioScience, Inc.  

8229 Postings, 4421 Tage Paradiso1NEWS

 
  
    #770
09.01.13 14:35
Amarantus BioScience Announces Positive Efficacy Data for MANF in a Nigral Delivery Neurorestoration Animal Model of Parkinson's Disease

2013-01-09 08:31 ET - News Release

SUNNYVALE, Calif., Jan. 9, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with protein misfolding and apoptosis centered around its patented therapeutic protein Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF), today presented positive preclinical efficacy data for MANF in a neurorestoration 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease. The data demonstrate that unlike Glial cell-Derived Neurotrophic Factor (GDNF), MANF significantly reduces behavioral deficits, increases dopaminergic (DA) nerve terminal reinnervation of the striatum, and increases dopamine concentrations in the striatum when MANF is administered directly to the substantia nigra (SNc). GDNF is an agent currently in clinical trials for Parkinson's disease. Dr. John W. Commissiong, Chief Scientific Officer of Amarantus, presented the data at the OneMedForum 2013 conference on January 8, 2013. The webcast is available online at http://www.onemedplace.com/database/list/cid/13336/.

"Today's data support previously reported behavioral data where MANF demonstrated superiority over GDNF," said Dr. John W. Commissiong. "Going forward, the Company is in a strong position to advance MANF as a potential disease-modifying treatment for Parkinson's based on unique behavioral, morphological and neurochemical data in standard animal models of the disease."

In humans and animals, dopamine is a chemical released by DA neurons to send signals to other neurons, and is known as a neurotransmitter. DA neurons are the cells responsible for releasing dopamine, and degenerate in the SNc of Parkinson's disease patients. This degeneration causes DA nerve terminals from the striatum to retract towards their cells bodies in the SNc. The loss of DA nerve terminals in the striatum leads to reduced dopamine levels in the striatum. Therefore, drug treatment to the SNc that increases innervation of the striatum is critical as a basis for functional recovery in Parkinson's disease.

The data produced comparing optimal doses to the SNc of MANF = 10 ug and GDNF = 10 ug in this model indicate the following at four weeks post-treatment:

1. MANF reduced behavioral deficits by 53%, whereas behavioral deficits with GDNF increased by 20%;
2. MANF produced a 14.4% reinnervation of the striatum, whereas striatum innervation with GDNF was reduced by 9.9%;
3. MANF increased dopamine concentrations in the striatum, whereas striatum dopamine concentrations with GDNF did not increase.

"We are excited about our results with MANF as we have demonstrated superiority to GDNF in a number of key areas related to recovery of function in Parkinson's disease," added Dr. Joseph Rubinfeld, Amarantus advisor and Amgen Co-Founder. "We intend to continue to move our Parkinson's program forward, while also evaluating other disease indications for MANF with potentially accelerated regulatory pathways, including certain orphan diseases. This strategy may significantly reduce MANF's overall time to market versus a Parkinson's-only strategy."

In the study, rodents were lesioned with 6-OHDA on one side of their brain (t = 0). Behavior was tested for baseline (t =1 week) and vehicle, MANF (3 ug, 10 ug or 36 ug) and GDNF (10ug) were injected in different groups of animals at t = 2 weeks. Behavior was tested for drug effect at t = 4 weeks (2 weeks post-treatment) and at t = 6 weeks (4 weeks post-treatment).

The behavioral data achieved statistical significance with a p value of less than 0.03 with animal groups of N=12. The striatum reinnervation data and dopamine concentration data did not achieve statistical significance because the animals sacrificed from the behavioral study were divided into 2 separate groups of N=6 for the analysis of densitometry (striatum reinnervation) and neurochemistry (dopamine concentration in the striatum). The method of analysis of the rat brains did not allow for the densitometry and neurochemistry to be analyzed simultaneously in the same animals, leading to groups of N = 6 or less, which was insufficient to achieve statistical significant.

The Company believes the data are positive, even without statistical significance due to small groups of animals in the densitometry and chemistry data, because there are consistent internal results correlating behavior, stereology, densitometry and neurochemistry, most notably at MANF = 10 ug and GDNF = 10ug. The Company is preparing to initiate IND enabling studies for MANF as a disease-modifying drug candidate for Parkinson's disease.

About Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF)

MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a protein that corrects protein misfolding, one of the major causes of apoptosis (Programmed Cell Death). Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) is believed to have broad potential because it is a naturally-occurring protein produced by the body for the purpose of reducing and preventing apoptosis (in response to injury or disease), via the unfolded protein response. By manufacturing MANF and administering it to the body, Amarantus is seeking to use a regenerative medicine approach to assist the body with higher quantities of MANF when needed. Amarantus is the front-runner and primary holder of intellectual property (IP) around MANF, and is initially focusing on the development of MANF-based protein therapeutics. MANF's current lead indication is Parkinson's disease with additional focus on Traumatic Brain Injury (TBI). Future indications may include myocardial infarction and certain rare and ultra-rare orphan diseases where MANF is currently being evaluated.

The Company also owns an inventory of 88 cell lines referred to as "PhenoGuard Cell Lines." MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line, and it is anticipated that additional therapeutic proteins useful for various therapeutic approaches to the Central Nervous System will be identified from the Company's inventory of PhenoGuard Cell Lines.

About Amarantus BioScience, Inc.

Amarantus BioScience, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit www.Amarantus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

MEDIA CONTACTS

Amarantus BioScience, Inc.
(408) 737-2734
pr@amarantus.com

Investor/Media Contact:
IR Sense, LLC
Remy Bernarda
415-203-6386
remy@irsense.com

SOURCE Amarantus BioScience, Inc.  

31878 Postings, 5350 Tage tbhomyNews deckt sich mit Inhalt der Präs. von gestern.

 
  
    #771
09.01.13 14:38

31878 Postings, 5350 Tage tbhomyWichtiger sind Hinweise auf...

 
  
    #772
09.01.13 14:42
...Feedbacks und Ausblick, auch und vor Allem kommerzieller Art.

Kommt ggfls. morgen etwas nach der zweiten Präsentation.  

4020 Postings, 5044 Tage ManuBabyMilchKaffe

 
  
    #773
1
09.01.13 14:45
Kannst dir alles über OTC-Markets anzeigen lassen.

http://www.otcmarkets.com/stock/AMBS/company-info  

2166 Postings, 5040 Tage MilchKaffeeDie Short Sales von gestern wären interessant

 
  
    #774
09.01.13 14:50

14689 Postings, 5176 Tage falke2@MilchKaffee

 
  
    #775
1
09.01.13 14:53

Seite: < 1 | ... | 28 | 29 | 30 |
| 32 | 33 | 34 | ... 67  >  
   Antwort einfügen - nach oben